Santen Pharmaceutical Co., Ltd.
Stock Forecast, Prediction & Price Target
Santen Pharmaceutical Co., Ltd. Financial Estimates
Santen Pharmaceutical Co., Ltd. Revenue Estimates
Santen Pharmaceutical Co., Ltd. EBITDA Estimates
Santen Pharmaceutical Co., Ltd. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 3/31/2022 | 3/31/2023 | 3/31/2024 | 3/31/2026 | 3/31/2027 | 3/31/2028 | 3/31/2029 |
Revenue
% change YoY
| $266.25B N/A | $279.03B 4.79% | $301.96B 8.21% | Avg: $270.59B Low: $242.01B High: $295.83B avg. -10.38% | Avg: $275.20B Low: $253.32B High: $294.00B avg. 1.70% | Avg: $314.18B Low: $289.20B High: $335.63B avg. 14.16% | Avg: $332.50B Low: $306.07B High: $355.20B avg. 5.83% |
Net Income
% change YoY
| $27.21B N/A | $-14.94B -154.91% | $26.64B 278.23% | Avg: $34.60B Low: $24.63B High: $45.33B avg. 29.89% | Avg: $37.44B Low: $33.57B High: $40.76B avg. 8.20% | Avg: $48.82B Low: $43.78B High: $53.16B avg. 30.40% | Avg: $57.32B Low: $51.40B High: $62.41B avg. 17.40% |
EBITDA
% change YoY
| $53.88B N/A | $12.94B -75.96% | $50.71B 291.65% | Avg: $44.18B Low: $39.51B High: $48.30B avg. -12.88% | Avg: $44.93B Low: $41.36B High: $48.00B avg. 1.70% | Avg: $51.29B Low: $47.22B High: $54.80B avg. 14.16% | Avg: $54.29B Low: $49.97B High: $57.99B avg. 5.83% |
EPS
% change YoY
| $68.07 N/A | -$38.58 -156.67% | $72.35 287.53% | Avg: $94 Low: $66.92 High: $123.15 avg. 29.92% | Avg: $101.71 Low: $91.2 High: $110.74 avg. 8.20% | Avg: $132.63 Low: $118.93 High: $144.41 avg. 30.40% | Avg: $155.72 Low: $139.63 High: $169.54 avg. 17.40% |
Operating Expenses
% change YoY
| $120.7B N/A | $169.17B 40.16% | $140.16B -17.14% | Avg: $85.93B Low: $76.85B High: $93.94B avg. -38.69% | Avg: $87.39B Low: $80.44B High: $93.36B avg. 1.70% | Avg: $99.77B Low: $91.84B High: $106.58B avg. 14.16% | Avg: $105.59B Low: $97.19B High: $112.80B avg. 5.83% |
FAQ
What is Santen Pharmaceutical Co., Ltd. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 21.47% in 2026-2029.
We have gathered data from 3 analysts. Their low estimate is 24.63B, average is 34.60B and high is 45.33B.
What is Santen Pharmaceutical Co., Ltd. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 2.82% in 2026-2029.
We have gathered data from 3 analysts. Their low revenue estimate is $242.01B, average is $270.59B and high is $295.83B.
What is Santen Pharmaceutical Co., Ltd. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 21.48% in 2026-2029.
We have gathered data from 3 analysts. Their low earnings per share estimate is $66.92, average is $94 and high is $123.15.